公司简介
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid...
关联新闻
- Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.
The biotech plans to reinvest in its pipeline, particularly oncology treatments like its personalized cancer vaccine.
- The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment
Look at the promising data for Moderna and Merck's experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
- GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
British drugmaker GSK has settled lawsuits that accused Moderna's [COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, the companies said on Friday.
- Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts.
Moderna posts higher-than-expected revenue as results get a lift from international Covid vaccine demand.
- Moderna Lifts Full-Year Outlook, Swings to Quarterly Profit
The biopharmaceutical company said Friday it now expects total revenue growth of 15% to 25% for the year, compared with a previous outlook for up to 10% growth.
- Moderna's stock jumps after biotech raises sales outlook
The company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026.
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week
In another busy earnings week, AMD, Estée Lauder, Qualcomm, Pfizer, and many more will report results. We'll see three readings on jobs this week, as well as data on the manufacturing and services sec...
- Moderna's CEO told The Wall Street Journal that his cancer vaccine's data will get better with time, and that no one can easily copy the company's work
Stéphane Bancel defended his melanoma data and argued that rivals can't easily copy the technology.